Conclusion
A recently completed randomized clinical trial demonstrated the safety
and efficacy of the convergent approach.3 Yet,
real-world, long-term evidence is generally lacking. This study
demonstrated that patients with more complex forms of AF (PAF refractory
to both AAD and index cryoballoon ablation and persistent/LSPAF) could
be well managed with a convergent approach. Moreover, outcomes match
safety and efficacy thresholds achieved by patients with an early, less
complex AF etiology treated by cryoballoon PVI-alone.
Acknowledgements: None
Disclosures: None